Researchers assessed whether increased systolic and diastolic blood pressure are associated with greater cardiovascular risks among patients with new-onset coronary artery disease or cerebrovascular disease, regardless of glucose status.
This report draws on the work of several sources, including a diverse group of experts at a recent conference that discussed health inequities magnified by the COVID-19 pandemic.
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Researchers conducted a systematic review and meta-analysis about the association of insomnia disorder characterized by objective sleep duration with hypertension, diabetes, and body mass index.
Intensive blood pressure treatment targeting systolic blood pressure <120 mm Hg results in lower rates of major adverse cardiovascular events and lower all-cause mortality than a standard treatment target among patients at increased cardiovascular risk.
